SXL
REGN icon

Summit X LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Summit X LLC’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-288
Closed -$303K – 232
2024
Q3 		$303K Sell
288
-5
-2% -$5.56K 0.07% 157
2024
Q2 		$308K Buy
293
+5
+2% +$4.85K 0.07% 173
2024
Q1 		$277K Sell
288
-546
-65% -$519K 0.07% 165
2023
Q4 		$732K Sell
834
-18
-2% -$14.8K 0.21% 90
2023
Q3 		$702K Sell
852
-9
-1% -$7.07K 0.22% 87
2023
Q2 		$619K Sell
861
-73
-8% -$56.3K 0.15% 139
2023
Q1 		$767K Sell
934
-12
-1% -$9.05K 0.2% 109
2022
Q4 		$559K Sell
946
-1
-0.1% -$738 0.16% 140
2022
Q3 		$654K Buy
947
+1
+0.1% +$629 0.19% 116
2022
Q2 		$558K Sell
946
-91
-9% -$59.2K 0.16% 140
2022
Q1 		$720K Sell
1,037
-732
-41% -$463K 0.18% 119
2021
Q4 		$1.12M Sell
1,769
-64
-3% -$39.3K 0.26% 90
2021
Q3 		$1.11M Sell
1,833
-519
-22% -$322K 0.28% 84
2021
Q2 		$1.31M Buy
2,352
+20
+0.9% +$10.1K 0.33% 70
2021
Q1 		$1.1M Buy
2,332
+635
+37% +$309K 0.3% 81
2020
Q4 		$810K Buy
+1,697
New +$916K 0.24% 100
2020
Q2 		$464K Sell
744
-219
-23% -$124K 0.17% 128
2020
Q1 		$465K Buy
963
+5
+0.5% +$2.06K 0.22% 107
2019
Q4 		$361K Sell
958
-142
-13% -$47.8K 0.13% 180
2019
Q3 		$310K Buy
1,100
+54
+5% +$16K 0.12% 191
2019
Q2 		$309K Buy
1,046
+189
+22% +$62.9K 0.13% 191
2019
Q1 		$352K Buy
+857
New +$353K 0.15% 172

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Summit X LLC's REGN Position: Q4 2024 in Review

Summit X LLC sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 288 shares — an estimated $303K sold.

Summit X LLC first reported a position in REGN in Q1 2019 and held it in 22 quarters. The position peaked at $1.31M in Q2 2021. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Summit X LLC reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Summit X LLC sold 288 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $303K.
  • Summit X LLC first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 22 quarters.
  • Summit X LLC's Regeneron Pharmaceuticals position peaked at $1.31M in Q2 2021.
  • 1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Summit X LLC's 13F filing for Q4 2024, filed 7 Feb 2025.